vs
Bioventus Inc.（BVS）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
Rapid7, Inc.的季度营收约是Bioventus Inc.的1.4倍（$217.4M vs $157.9M），Bioventus Inc.净利率更高（9.3% vs 1.4%，领先7.9%），Bioventus Inc.同比增速更快（2.8% vs 0.5%），Bioventus Inc.自由现金流更多（$37.4M vs $36.4M），过去两年Bioventus Inc.的营收复合增速更高（10.4% vs 3.0%）
Bioventus Inc.是一家全球化医疗技术企业，专注于骨科生物制剂领域，研发并商业化促进骨关节愈合、肌肉骨骼疼痛管理及再生护理的相关产品，服务全球多地的骨科临床医师、康复师及患者群体。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
BVS vs RPD — 直观对比
营收规模更大
RPD
是对方的1.4倍
$157.9M
营收增速更快
BVS
高出2.3%
0.5%
净利率更高
BVS
高出7.9%
1.4%
自由现金流更多
BVS
多$964.0K
$36.4M
两年增速更快
BVS
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $157.9M | $217.4M |
| 净利润 | $14.8M | $3.1M |
| 毛利率 | 68.9% | 68.9% |
| 营业利润率 | 12.3% | 1.0% |
| 净利率 | 9.3% | 1.4% |
| 营收同比 | 2.8% | 0.5% |
| 净利润同比 | 3902.8% | 44.1% |
| 每股收益（稀释后） | $0.21 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BVSRPD
| Q4 25 | $157.9M | $217.4M | ||
| Q3 25 | $138.7M | $218.0M | ||
| Q2 25 | $147.7M | $214.2M | ||
| Q1 25 | $123.9M | $210.3M | ||
| Q4 24 | $153.6M | $216.3M | ||
| Q3 24 | $139.0M | $214.7M | ||
| Q2 24 | $151.2M | $208.0M | ||
| Q1 24 | $129.5M | $205.1M |
净利润BVSRPD
| Q4 25 | $14.8M | $3.1M | ||
| Q3 25 | $3.2M | $9.8M | ||
| Q2 25 | $7.5M | $8.3M | ||
| Q1 25 | $-2.6M | $2.1M | ||
| Q4 24 | $-388.0K | $2.2M | ||
| Q3 24 | $-5.2M | $15.4M | ||
| Q2 24 | $-25.7M | $6.5M | ||
| Q1 24 | $-4.9M | $1.4M |
毛利率BVSRPD
| Q4 25 | 68.9% | 68.9% | ||
| Q3 25 | 68.0% | 70.2% | ||
| Q2 25 | 69.1% | 70.6% | ||
| Q1 25 | 67.0% | 71.7% | ||
| Q4 24 | 66.8% | 69.5% | ||
| Q3 24 | 67.3% | 70.6% | ||
| Q2 24 | 68.5% | 70.7% | ||
| Q1 24 | 68.3% | 70.3% |
营业利润率BVSRPD
| Q4 25 | 12.3% | 1.0% | ||
| Q3 25 | 8.1% | 2.7% | ||
| Q2 25 | 12.4% | 1.6% | ||
| Q1 25 | 3.9% | -0.0% | ||
| Q4 24 | 5.0% | 3.4% | ||
| Q3 24 | 2.6% | 6.0% | ||
| Q2 24 | -20.8% | 2.5% | ||
| Q1 24 | 3.8% | 4.7% |
净利率BVSRPD
| Q4 25 | 9.3% | 1.4% | ||
| Q3 25 | 2.3% | 4.5% | ||
| Q2 25 | 5.1% | 3.9% | ||
| Q1 25 | -2.1% | 1.0% | ||
| Q4 24 | -0.3% | 1.0% | ||
| Q3 24 | -3.7% | 7.2% | ||
| Q2 24 | -17.0% | 3.1% | ||
| Q1 24 | -3.8% | 0.7% |
每股收益（稀释后）BVSRPD
| Q4 25 | $0.21 | $0.05 | ||
| Q3 25 | $0.05 | $0.15 | ||
| Q2 25 | $0.11 | $0.13 | ||
| Q1 25 | $-0.04 | $0.03 | ||
| Q4 24 | $0.00 | $0.08 | ||
| Q3 24 | $-0.08 | $0.21 | ||
| Q2 24 | $-0.40 | $0.09 | ||
| Q1 24 | $-0.08 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $51.2M | $474.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $184.1M | $154.7M |
| 总资产 | $683.6M | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BVSRPD
| Q4 25 | $51.2M | $474.7M | ||
| Q3 25 | $42.2M | $407.1M | ||
| Q2 25 | $32.9M | $511.7M | ||
| Q1 25 | $22.8M | $493.5M | ||
| Q4 24 | $41.6M | $521.7M | ||
| Q3 24 | $43.1M | $443.7M | ||
| Q2 24 | $32.0M | $442.6M | ||
| Q1 24 | $25.2M | $411.7M |
股东权益BVSRPD
| Q4 25 | $184.1M | $154.7M | ||
| Q3 25 | $166.1M | $127.2M | ||
| Q2 25 | $161.2M | $90.4M | ||
| Q1 25 | $148.1M | $52.7M | ||
| Q4 24 | $147.9M | $17.7M | ||
| Q3 24 | $148.7M | $-5.1M | ||
| Q2 24 | $150.9M | $-52.6M | ||
| Q1 24 | $171.3M | $-86.4M |
总资产BVSRPD
| Q4 25 | $683.6M | $1.7B | ||
| Q3 25 | $701.6M | $1.7B | ||
| Q2 25 | $706.8M | $1.6B | ||
| Q1 25 | $691.4M | $1.6B | ||
| Q4 24 | $728.0M | $1.7B | ||
| Q3 24 | $769.5M | $1.6B | ||
| Q2 24 | $792.2M | $1.5B | ||
| Q1 24 | $794.2M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $38.0M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $37.4M | $36.4M |
| 自由现金流率自由现金流/营收 | 23.7% | 16.8% |
| 资本支出强度资本支出/营收 | 0.4% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.57× | 12.01× |
| 过去12个月自由现金流最近4个季度 | $72.1M | $146.2M |
8季度趋势，按日历期对齐
经营现金流BVSRPD
| Q4 25 | $38.0M | $37.6M | ||
| Q3 25 | $30.1M | $39.0M | ||
| Q2 25 | $25.9M | $47.5M | ||
| Q1 25 | $-19.3M | $29.8M | ||
| Q4 24 | $19.3M | $63.8M | ||
| Q3 24 | $10.3M | $44.0M | ||
| Q2 24 | $15.2M | $32.9M | ||
| Q1 24 | $-6.0M | $31.1M |
自由现金流BVSRPD
| Q4 25 | $37.4M | $36.4M | ||
| Q3 25 | $29.6M | $34.8M | ||
| Q2 25 | $25.3M | $46.6M | ||
| Q1 25 | $-20.2M | $28.4M | ||
| Q4 24 | $18.7M | $62.6M | ||
| Q3 24 | $10.3M | $42.6M | ||
| Q2 24 | $15.1M | $32.6M | ||
| Q1 24 | $-6.3M | $30.4M |
自由现金流率BVSRPD
| Q4 25 | 23.7% | 16.8% | ||
| Q3 25 | 21.4% | 16.0% | ||
| Q2 25 | 17.1% | 21.8% | ||
| Q1 25 | -16.3% | 13.5% | ||
| Q4 24 | 12.2% | 28.9% | ||
| Q3 24 | 7.4% | 19.9% | ||
| Q2 24 | 10.0% | 15.7% | ||
| Q1 24 | -4.9% | 14.8% |
资本支出强度BVSRPD
| Q4 25 | 0.4% | 0.5% | ||
| Q3 25 | 0.3% | 1.9% | ||
| Q2 25 | 0.5% | 0.4% | ||
| Q1 25 | 0.7% | 0.6% | ||
| Q4 24 | 0.4% | 0.5% | ||
| Q3 24 | 0.0% | 0.6% | ||
| Q2 24 | 0.1% | 0.1% | ||
| Q1 24 | 0.2% | 0.3% |
现金转化率BVSRPD
| Q4 25 | 2.57× | 12.01× | ||
| Q3 25 | 9.54× | 3.97× | ||
| Q2 25 | 3.48× | 5.70× | ||
| Q1 25 | — | 14.14× | ||
| Q4 24 | — | 29.36× | ||
| Q3 24 | — | 2.85× | ||
| Q2 24 | — | 5.03× | ||
| Q1 24 | — | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BVS
| Pain Treatments | $71.1M | 45% |
| Surgical Solutions | $48.9M | 31% |
| Restorative Therapies | $19.5M | 12% |
| Other | $18.4M | 12% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
